HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $20
Altimmune Inc
Altimmune Inc ALT | 0.00 |
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:
ALT) with a Buy and lowers the price target from $25 to $20.
